Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
175 Clinical Paid Trials near Long Beach, CA
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerIPN10200 for Upper Limb Spasticity
Downey, California
This trial is testing a medication called IPN10200 to see how safe and effective it is for adults with stiff muscles in their arms. Researchers are trying different doses to find the best one that works well without causing too many side effects. The goal is to help reduce muscle stiffness in these patients.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Neuromuscular Disorders, Anxiety, Depression, Others
Must Not Be Taking:Antidepressants, Baclofen, Neuromuscular Blockers, Others
240 Participants Needed
SPY002-091 Safety Study in Healthy Volunteers
Cypress, California
This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Drug Abuse, Alcoholism, Smoking, Others
56 Participants Needed
LY4006895 for Alzheimer's Disease
Los Alamitos, California
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD).
Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it.
This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:45 - 85
Key Eligibility Criteria
Disqualifiers:Serious Illnesses, Suicidal, Drug Abuse, Others
Must Not Be Taking:Anti-tau, Amyloid Therapies
88 Participants Needed
BI 1356225 for Opioid Use Disorder
Los Alamitos, California
This study is open to men between 18 and 65 years of age with opioid use disorder. Opioid use disorder is also called opioid addiction or opioid dependence. People can join the study if they currently take a medicine called buprenorphine. People with opioid dependence can act on impulse, which can lead to risky behaviours. The purpose of this study is to find out whether a medicine called BI 1356225 improves impulse control in men with opioid dependence.
Participants are put into 2 groups by chance. One group takes BI 1356225 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1356225 tablets but do not contain any medicine. Participants take a tablet once a day for 8 days. All participants also continue taking buprenorphine.
Participants are in the study for up to 6 weeks. During this time, they visit the study site 3 times. At visit 2, participants stay at the study site for 9 nights. Doctors test participants' impulsivity using tasks or games on a computer and questionnaires. The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:Male
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Severe Stimulant Use, Others
Must Be Taking:Buprenorphine
60 Participants Needed
mRNA Vaccine for RSV
Rolling Hills Estates, California
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 45
Key Eligibility Criteria
Disqualifiers:Immunodeficient, HIV, HBV, HCV, Others
Must Not Be Taking:Immune-modifying Drugs
213 Participants Needed
SPY001-001 for Healthy Subjects
Cypress, California
This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Drug Abuse, Alcoholism, Smoking, Others
96 Participants Needed
Orforglipron for Obesity
Los Alamitos, California
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated.
The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Diabetes, Cardiovascular, Psychiatric, Others
508 Participants Needed
LP-284 for Cancer
Los Alamitos, California
This trial tests a new drug, LP-284, in adults with hard-to-treat cancers. It aims to find the safest dose and understand how the drug works in the body.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:CNS Lymphoma, Active Malignancy, Unstable Cardiovascular, Hepatitis, Others
110 Participants Needed
AFA-281 Safety Study in Healthy Volunteers
Los Alamitos, California
This trial tests a new drug, AFA-281, in healthy volunteers to check its safety and how it behaves in the body. Volunteers take the drug for a short period. Researchers measure drug levels in the blood and monitor for any side effects.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Significant Medical History, Others
58 Participants Needed
HBI-2438 for Cancer with KRAS G12C Mutation
Long Beach, California
This trial tests HBI-2438, an oral drug for patients with advanced solid tumors having the KRAS G12C mutation. The drug aims to stop cancer growth by blocking the faulty gene. Related drugs, Adagrasib and Sotorasib, have shown effectiveness in treating similar conditions.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Concurrent Malignancy, CNS Metastases, Cardiovascular Disease, Autoimmune Diseases, Others
Must Not Be Taking:Steroids, Immunosuppressants, KRAS Inhibitors
44 Participants Needed
BI 1810631 for Advanced Cancer
Huntington Beach, California
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Major Surgery, Previous Malignancies, Others
Must Not Be Taking:Systemic Anti-cancer, Investigational Drugs
554 Participants Needed
Hormonal Treatments for Sleep Deprivation
Torrance, California
The purpose of this study is to 1) determine how hypothalamic-pituitary-adrenal axis (HPA axis) activation occurs with sleep restriction and 2) evaluate how hypothalamic-pituitary-gonadal axis (HPG axis) deactivation occurs with sleep restriction. The investigator will also examine the cognitive function associated with sleep restriction, including food intake and food cravings.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:60 - 80
Key Eligibility Criteria
Disqualifiers:Not Listed
5 Participants Needed
Inno8 Absorption Study
Cypress, California
The purpose of this study is to test a new medicine called Inno8. The study will test how eating and drinking before and after taking Inno8 affects how well it is absorbed in the stomach. The study consists of four arms. Participants will take the study medicine after an overnight fast. How long participants will need to fast depends on which group participants are in. After taking the study medicine, participants will need to fast again. The study will last for up to 9.5 weeks.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 45
Sex:Male
Key Eligibility Criteria
Disqualifiers:Thrombosis, Coagulation Disorders, Gastrointestinal, Others
80 Participants Needed
Semaglutide + Liraglutide for Obesity
Cypress, California
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, Gastrointestinal Disorders, Renal Impairment, Others
Must Be Taking:GLP-1 Medications
75 Participants Needed
VS-041 for Heart Failure
Torrance, California
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Lung Disease, Malignancy, Others
42 Participants Needed
Emraclidine in Healthy Elderly Adults
Cypress, California
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:65 - 85
Key Eligibility Criteria
Disqualifiers:Cardiac, Respiratory, Renal, Hepatic, Others
32 Participants Needed
NNC0662-0419 for Obesity
Cypress, California
The study is testing the new medicine NNC0662-0419 in people living with overweight or obesity. The purpose of the study is to look into the amount of the new medicine NNC0662-0419 in participants blood after one dose. And also look into how safe and how well the study medicine is tolerated in people living with overweight or obesity. NNC0662-0419 is a new medicine which cannot be prescribed by doctors. NNC0662-0419 is currently being tested in humans and the dose participants will receive has been found safe and tolerable. Participants will get a single dose of NNC0662-0419 given by study staff as a single injection under participants skin. Like all medicines, the study medicine may have side effects. The study will last up to 2 months.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Hypersensitivity, ECG Abnormalities, High HbA1c, Others
99 Participants Needed
KarXT for Schizophrenia
Los Alamitos, California
The purpose of this study is to evaluate the dose levels, safety, and drug levels of KarXT intramuscular injection in participants with Schizophrenia
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:New Schizophrenia, Major Depression, Others
Must Not Be Taking:Antipsychotics
48 Participants Needed
Pralatrexate for Cancer
Cerritos, California
This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing recommendations for pralatrexate administered once weekly for 6 weeks of every 7-week treatment cycle in patients with hepatic impairment. Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pralatrexate Exposure, CNS Metastases, Others
Must Not Be Taking:Investigational Drugs
24 Participants Needed
Risankizumab Administration Methods for Healthy Subjects
Cypress, California
This study will assess the pharmacokinetics, relative bioavailability, immunogenicity, safety, and tolerability of risankizumab following subcutaneous (SC) administration with a prefilled pen or a prefilled syringe in healthy adult participants.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 60
Key Eligibility Criteria
Disqualifiers:Strenuous Exercise, Others
Must Not Be Taking:Anti-interleukin-12/23
59 Participants Needed
Why Other Patients Applied
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
Risankizumab for Healthy Subjects
Los Alamitos, California
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 60
Key Eligibility Criteria
Disqualifiers:Strenuous Exercise, Others
Must Not Be Taking:Anti-interleukin-12/23
263 Participants Needed
IDB-011 Safety Study
Cypress, California
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:RVFV Infection, Malignancy, Cardiovascular, HIV, Others
40 Participants Needed
MET233 + MET097 for Obesity
Cypress, California
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, Hypertension, Type 1 Diabetes, Others
Must Not Be Taking:Glucose-lowering Medications
132 Participants Needed
Lithium + Valproic Acid + KarXT for Healthy Subjects
Los Alamitos, California
The purpose of this study is to evaluate the effects of lithium, valproic acid, and lamotrigine on the single-dose pharmacokinetics (PK) of KarXT and the effect of KarXT on the single-dose PK of lithium, valproic acid, and lamotrigine in healthy participants.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Hepatic, Renal, Pancreatitis, Others
130 Participants Needed
PRX019 for Healthy Participants
Los Alamitos, California
The purpose of this study is to assess the safety and tolerability of PRX019 in healthy adult participants.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Organ Dysfunction, Recent Investigational Drug, Others
48 Participants Needed
Lumateperone for Schizophrenia
Los Alamitos, California
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Other Psychiatric Conditions, Suicidal Ideation, Others
72 Participants Needed
LY3537031 for Obesity
Los Alamitos, California
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants.
Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 48 weeks excluding a screening period.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:22 - 65
Key Eligibility Criteria
Disqualifiers:Bariatric Surgery, Lactating, High Calcitonin, Others
Must Not Be Taking:Weight Loss Drugs
302 Participants Needed
NMRA-323511 for Agitation in Alzheimer's Disease
Lomita, California
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.
Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.
Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment.
Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Epilepsy, Suicidal, Neurologic Disorder, Others
Must Not Be Taking:Anticonvulsants
96 Participants Needed
TV-44749 vs Oral Olanzapine for Schizophrenia
Torrance, California
The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia.
A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia.
Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia.
The total duration of participation in the trial for each participant is planned to be approximately 21 weeks.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Diabetes, Hepatic Disorder, Arrhythmia, Others
Must Be Taking:Olanzapine
116 Participants Needed
TORL-4-500 for Advanced Cancer
Torrance, California
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.
For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiac Disease, MDS, Others
Must Not Be Taking:Chemotherapy, Biologics
70 Participants Needed
Know someone looking for new options?
Spread the word